RESULTS OF RESECTION FOR BRONCHOGENIC-CARCINOMA WITH MEDIASTINAL LYMPH-NODE METASTASES IN SELECTED PATIENTS

被引：30

作者：

REGNARD, JF

MAGDELEINAT, P

AZOULAY, D

DARTEVELLE, P

DENEUVILLE, M

ROJASMIRANDA, A

LEVASSEUR, P

机构：

[1] Department of Thoracic and Digestive Surgery, Marie Lannelongue Hospital, Le Plessis

来源：

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY | 1991年 / 5卷 / 11期

关键词：

BRONCHOGENIC CARCINOMA; RESECTION; MEDIASTINAL LYMPH NODE INVOLVEMENT; SELECTION OF INDICATION;

D O I：

10.1016/1010-7940(91)90224-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Between 1982 and 1988, 254 consecutive patients underwent resection for bronchogenic carcinoma with mediastinal lymph node metastases at Marie Lannelongue Hospital. Selection of cases for surgery was carried out using CT and mediastinoscopy. The surgical procedure performed were pneumonectomy (169), lobectomy (65), or bilobectomy (20) associated with resection of ipsilateral mediastinal lymph nodes. Almost all diseased nodes appeared grossly enlarged at surgery and only a few were of normal size. Postoperative mortality was 5.6%. Resection was potentially curative in 191 cases (75%) and palliative in 63 cases (25%). Almost all patients received adjuvant treatment (mainly radiotherapy). Actuarial 5-year survival was 18% for the entire group, and 23% for those who underwent curative resection. No patient with palliative resection survived 5 years. The following factors proved to be significantly associated with a better prognosis: complete resection, independent lymph node metastases, involvement of only one level, lower paratracheal involvement. On the other hand, there was no difference between pathological types (squamous cell carcinomas, adenocarcinomas, oat cell carcinomas) with regard to prognosis. We advocate an aggressive approach in selected cases of N2 bronchogenic carcinoma. Neoadjuvant chemotherapy should be tested in these specific patients with a view to the possibility of improving results.

引用

页码：583 / 587

页数：5

共 15 条

[1]

Backer C.L., Shields T.W., Lockhart C.G., Vogelzang R., Lo Cicero J., Selective preoperative evaluation for possible N2 disease in carcinoma of the lung, J Thorac Cardiovasc Surg, 93, pp. 337-341, (1987)

[2]

Coughlin M., Deslauriers J., Beaulieu J.M., Fournier B., Piraux N., Role of mediastinoscopy in pre-treatment staging of patients with primary lung cancer, Ann Thorac Surg, 40, pp. 556-560, (1985)

[3]

Faber L.P., Kittle C.F., Warren W.H., Bonomi P.D., Taylor S.G., Preoperative chemotherapy and radiation for stage III non-small cell lung cancer, Ann Thorac Surg, 47, pp. 669-677, (1989)

[4]

Holmes E.C., Hill L.D., Gail M., A randomized comparison of the effects of adjuvant therapy on resected stages II and III non-small cell carcinoma of the lung, Ann Surg, 202, pp. 335-341, (1985)

[5]

Maggi G., Casadio C., Mancuso M., Oliaro A., Cianci R., Ruffini E., Resection and radical lymphadenectomy for lung cancer Prognostic significance of lymphatic métastasés, Int Surg, 75, pp. 17-21, (1990)

[6]

Martini N., Flehinger B.J., The role of surgery in N2 lung cancer, Surg Clin North Am, 67, pp. 1037-1049, (1987)

[7]

Martini N., Flehinger B.J., Zaman M.B., Beattie E.J., Prospective study of 445 lung carcinomas with mediastinal node métastasés, J Thorac Cardiovasc Surg, 80, pp. 390-395, (1980)

[8]

Martini N., Kris M.G., Gralla R.J., The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal node métastasés (N2M0), Ann Thorac Surg, 35, pp. 370-379, (1988)

[9]

Naruke T., Goya T., Tsuchuiya R., Suemasu K., The importance of surgery to non-small cell carcinoma of the lung with mediastinal lymph node metastasis, Ann Thorac Surg, 46, pp. 603-610, (1988)

[10]

Patterson G.A., Piazza D., Pearson F.G., Todd T., Ginsberg R.J., Golberg R.J., Waters P., Jones D., Lives R., Cooper J.D., Significance of metastatic disease in subaortic lymph nodes, Ann Thorac Surg, 43, pp. 155-159, (1987)

← 1 2 →